{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T21:19:10Z","timestamp":1758057550378,"version":"3.44.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Cl\u00ednica Espa\u00f1ola"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.rce.2018.11.012","type":"journal-article","created":{"date-parts":[[2019,4,7]],"date-time":"2019-04-07T15:48:30Z","timestamp":1554652110000},"page":"440-444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["An\u00e1lisis integrado cl\u00ednico, molecular e histopatol\u00f3gico de la m\u00e9dula \u00f3sea en las neoplasias mieloproliferativas cr\u00f3nicas"],"prefix":"10.1016","volume":"219","author":[{"given":"L.","family":"Medina Vega","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Hern\u00e1ndez Nieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Salido Ru\u00edz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"\u00c1lvarez-Arg\u00fcelles Cabrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Raya S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rce.2018.11.012_bib0065","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.rce.2018.11.012_bib0070","first-page":"210","article-title":"Evaluaci\u00f3n sistem\u00e1tica de la biopsia de m\u00e9dula \u00f3sea en casos de sospecha de mielofibrosis primaria Propuesta de informe diagn\u00f3stico estandarizado. Consenso de expertos de las SEAP\/SEHH","volume":"47","author":"Montes-Moreno","year":"2014","journal-title":"Rev Esp Patol"},{"key":"10.1016\/j.rce.2018.11.012_bib0075","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL IDH and IKZF1","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.rce.2018.11.012_bib0080","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.rce.2018.11.012_bib0085","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.rce.2018.11.012_bib0090","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2008.113","article-title":"Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: A critical reappraisal","volume":"22","author":"Vannucchi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.rce.2018.11.012_bib0095","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","article-title":"JAK2 mutation in essential thrombocythaemia: Clinical associations and long-term prognostic relevance","volume":"131","author":"Wolanskyj","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rce.2018.11.012_bib0100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I","article-title":"Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted County Study, 1976-1995","volume":"61","author":"Mesa","year":"1999","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rce.2018.11.012_bib0105","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.rce.2018.11.012_bib0110","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s00277-014-2151-8","article-title":"Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia","volume":"93","author":"Chen","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.rce.2018.11.012_bib0115","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bjh.12990","article-title":"WHO-histological criteria for myeloproliferative neoplasms: Reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes","volume":"166","author":"Alvarez-Larran","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rce.2018.11.012_bib0120","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1309\/AJCPUAAC16LIWZMM","article-title":"CALR JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable","volume":"143","author":"Kim","year":"2015","journal-title":"Am J Clin Pathol"}],"container-title":["Revista Cl\u00ednica Espa\u00f1ola"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014256519300426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014256519300426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T21:38:42Z","timestamp":1757972322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014256519300426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0014256519300426"],"URL":"https:\/\/doi.org\/10.1016\/j.rce.2018.11.012","relation":{},"ISSN":["0014-2565"],"issn-type":[{"type":"print","value":"0014-2565"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An\u00e1lisis integrado cl\u00ednico, molecular e histopatol\u00f3gico de la m\u00e9dula \u00f3sea en las neoplasias mieloproliferativas cr\u00f3nicas","name":"articletitle","label":"Article Title"},{"value":"Revista Cl\u00ednica Espa\u00f1ola","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rce.2018.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Medicina Interna (SEMI). All rights reserved.","name":"copyright","label":"Copyright"}]}}